We are live on ! Find out more
TMBR

Timber Pharmaceuticals, Inc.

Delisted

TMBR was delisted on the 28th of November, 2023.

15 hedge funds and large institutions have $2.23M invested in Timber Pharmaceuticals, Inc. in 2021 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

168% more capital invested

Capital invested by funds: $835K → $2.23M (+$1.4M)

40% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 5

15% more funds holding

Funds holding: 1315 (+2)

Holders
15
Holders Change
+2
Holders Change %
+15.38%
% of All Funds
0.26%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
5
Reduced
1
Closed
5
Calls
Puts
Net Calls
Net Calls Change

TMBR Hedge Fund Activity: Q2 2021 in Review

15 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Timber Pharmaceuticals, Inc. (TMBR) for Q2 2021, worth a combined $2.23M — up 168% from $835K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new TMBR positions and 5 closed out — a net gain of 2 holders — while 5 added to existing stakes and 1 trimmed.

The largest buyer was Vanguard Group, adding an estimated $1.28M. The largest seller was Cetera Advisor Networks, exiting entirely with an estimated $207K sold.

  • 15 institutional investors held Timber Pharmaceuticals, Inc. (TMBR) as of Q2 2021, up from 13 in Q1 2021.
  • Funds reported $2.23M of Timber Pharmaceuticals, Inc. stock for Q2 2021, up 168% quarter-over-quarter.
  • 7 funds opened new Timber Pharmaceuticals, Inc. positions in Q2 2021 and 5 closed out, a net change of +2 holders.
  • The largest Timber Pharmaceuticals, Inc. buyer in Q2 2021 was Vanguard Group, an estimated $1.28M added.
  • The largest Timber Pharmaceuticals, Inc. seller in Q2 2021 was Cetera Advisor Networks, an estimated $207K sold.

Based on aggregated 13F filings for Q2 2021.